203 related articles for article (PubMed ID: 27878277)
1. Synthetic paclitaxel-octreotide conjugate reverses the resistance of paclitaxel in A2780/Taxol ovarian cancer cell line.
Shen Y; Zhang XY; Chen X; Fan LL; Ren ML; Wu YP; Chanda K; Jiang SW
Oncol Rep; 2017 Jan; 37(1):219-226. PubMed ID: 27878277
[TBL] [Abstract][Full Text] [Related]
2. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.
Chen X; Zhang XY; Shen Y; Fan LL; Ren ML; Wu YP
Oncotarget; 2016 Dec; 7(50):83451-83461. PubMed ID: 27825139
[TBL] [Abstract][Full Text] [Related]
3. Octreotide reverses the resistance of A2780/Pacliaxel ovarian cancer cell line to paclitaxel chemotherapy in vitro.
Shen Y; Zhang XY; Chen X; Ren ML; Cai YL
J Cancer Res Ther; 2016; 12(2):657-62. PubMed ID: 27461627
[TBL] [Abstract][Full Text] [Related]
4. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y
Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374
[TBL] [Abstract][Full Text] [Related]
5. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
[TBL] [Abstract][Full Text] [Related]
6. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
7. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
[No Abstract] [Full Text] [Related]
8. [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel].
Xiao L; Gao R; Lu S; Lu MS; Liang ML; Ren LR; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):412-6. PubMed ID: 17697605
[TBL] [Abstract][Full Text] [Related]
9. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
Sun NK; Huang SL; Chang TC; Chao CC
J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
[TBL] [Abstract][Full Text] [Related]
11. Cepharanthine hydrochloride reverses P‑glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway.
Huang CZ; Wang YF; Zhang Y; Peng YM; Liu YX; Ma F; Jiang JH; Wang QD
Oncol Rep; 2017 Oct; 38(4):2558-2564. PubMed ID: 28791369
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
14. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
15. Targeted paclitaxel-octreotide conjugates inhibited the growth of paclitaxel-resistant human non-small cell lung cancer A549 cells in vitro.
Liu Y; Xia H; Wang Y; Han W; Qin J; Gao W; Qu X; Wang X
Thorac Cancer; 2021 Nov; 12(22):3053-3061. PubMed ID: 34617400
[TBL] [Abstract][Full Text] [Related]
16. [Expression of microRNA 27a and its correlation with drug resistance in human ovarian cancer A2780/Taxol cells].
Li ZM; Hu S; Xiao L; Wang J; Cai J; Yu LL; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):372-5. PubMed ID: 20646448
[TBL] [Abstract][Full Text] [Related]
17. HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
Li Y; Sun J; Gao S; Hu H; Xie P
Gene; 2018 Jul; 663():9-16. PubMed ID: 29660518
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
Xu Y; Zhang J; Wu J; Zhong S; Li H
Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
[TBL] [Abstract][Full Text] [Related]
19. 3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of taxol resistant human ovarian cancer by inhibiting multidrug resistance (MDR) proteins function.
Jin L; Yingchun W; Zhujun S; Yinan W; Dongchen W; Hui Y; Xi Y; Wanzhou Z; Buluan Z; Jinhua W
Biomed Pharmacother; 2019 Aug; 116():108992. PubMed ID: 31129513
[TBL] [Abstract][Full Text] [Related]
20. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192
[No Abstract] [Full Text] [Related]
[Next] [New Search]
